Pertinax provides sustained, controlled antimicrobial protection for medical devices, biomaterials and in topical formulations.
Pertinax Pharma are supported by an experienced management team and a highly skilled and versatile team of scientists.
Get in touch to learn more about our technology and to discuss how Pertinax might be used in your products.
Get In Touch
About Pertinax Pharma
Pertinax formed in 2015, as a spin-out from the University of Bristol. The technology was initially developed in the laboratory of Dr Michele Barbour, CEO. Michele is supported by an experienced management team and a dynamic and dedicated team of scientists.
Find out the latest news and information from Pertinax.
We are raising capital @SyndicateRoom. Our funding round is at 95% – for sophisticated investors only & CapitalAtRisk - further information … Read More about Pertinax are raising capital on SyndicateRoom
We are delighted to announce that the Pertinax patents have been formally assigned to Pertinax Pharma. Previously, the patents were owned by the University of Bristol and licensed to the company on an exclusive, royalty-free basis. … Read More about Pertinax patents assigned!
Earlier this year we were lucky enough to host an intern from the SWBio Doctoral Training Partnership, funded by BBSRC. Cat Tooke stepped out of her PhD at the University of Bristol and became a much valued member of Team Pertinax. She has … Read More about Pertinax intern Cat talks about her internship